Sanofi Receives Indian Marketing Approval for Dupixent to treat Adults with Moderate-to-Severe Atopic Dermatitis

Sanofi Healthcare India Pvt. Ltd. announced that Dupixent (dupilumab), the first biologic medicine for the treatment of moderate-to-severe atopic dermatitis in adults whose disease is not adequately controlled with topical prescription therapies or when those therapies are contraindicated, has received marketing authorization. Dupixent can be used in conjunction with or in place of topical therapy. Dupixent has transformed the treatment landscape for patients worldwide by targeting the type 2 inflammation that underpins the disease rather than suppressing the immune system broadly.

"Dupixent receiving marketing authorization in India is a significant milestone, as we now have the opportunity to offer our first-in-class and best-in-class therapy to treat people living with atopic dermatitis in India," said Anil Raina, general manager, Sanofi Specialty Care (India). Atopic dermatitis, a type of eczema, is a chronic type 2 inflammatory disease characterised by a skin rash. Atopic dermatitis is characterized by rashes that often cover the entire body and can include intense, persistent itching, skin dryness, cracking, redness, crusting, and oozing. "The prevalence of atopic dermatitis in adults in India ranges from 2% to 8%, and there has been a trend of increasing prevalence observed in India," said Dr. Shalini Menon, country medical lead, Sanofi (India).

Many people struggle to control their disease with the current treatment options. With more than 600,000 patients being treated with Dupixent globally, Dupixent will soon be available as an option for controlling moderate to severe atopic dermatitis for adults in India. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. Since 1956, Sanofi has earned the trust as well as a place in 1-in-3 Indian households (if not more). Pain management (Combiflam), respiratory allergies caused by pollution (Allegra), vitamin D deficiency (Depura), diabetes (Lantus - insulin glargine), flu prevention (FluQuadri vaccine) and rare diseases (4 first & best-in-class therapies) are significant health issues, and our portfolio helps prevent, treat or optimally manage them. Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases.